Paul Knoll
Urology · Nashville, TNNPI 1932528411
Payments from drug & device makers
Across 285 payments — averaging $38.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Procept Biorobotics Corporation$660
- Pfizer$521
- Sumitomo Pharma America, Inc.$520
- Laborie Medical Technologies Corp.$425
- Endo Pharmaceuticals Inc.$388
- plus $2K from 31 others
What the payments were for
- Travel & lodging$1,99018%
- Food & beverage$8,91281%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 117 | $6,036 |
| Procept Biorobotics Corporation | 10 | $660 |
| Pfizer | 29 | $521 |
| Sumitomo Pharma America, Inc. | 24 | $520 |
| Laborie Medical Technologies Corp. | 7 | $425 |
| Endo Pharmaceuticals Inc. | 11 | $388 |
| Teleflex LLC | 3 | $264 |
| Coloplast | 8 | $255 |
| AbbVie(2 entities) | 8 | $213 |
| Axonics, Inc. | 4 | $163 |
| Innovation Technologies Inc | 1 | $142 |
| Urogen Pharma, Inc. | 5 | $122 |
| Astellas Pharma US Inc | 7 | $113 |
| Agiliti Health, Inc. | 2 | $105 |
| Cook Medical LLC | 1 | $98 |
| Urovant Sciences Inc | 6 | $98 |
| Myovant Sciences Inc. | 7 | $98 |
| Johnson & Johnson | 3 | $81 |
| Cook Biotech Incorporated | 1 | $79 |
| AstraZeneca | 4 | $74 |
| Blue Earth Diagnostics | 3 | $72 |
| Dendreon Pharmaceuticals LLC | 2 | $58 |
| Verity Pharmaceuticals Inc. | 3 | $58 |
| Ferring Pharmaceuticals Inc. | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Endo USA, Inc. | 2 | $37 |
| Clarus Therapeutics Inc. | 2 | $31 |
| Ambu Inc. | 1 | $30 |
| Tolmar, Inc. | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 2 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Olympus America Inc. | 1 | $13 |
| RTI Surgical, Inc | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$711
- TACTRA$461
- AMS 700 CXR RTE KIT$355
- AquaBeam Robotic System$271
- AMS 700$261
- GENERAL ERECTILE DYSFUNCTION$260
- AQUABEAM SYSTEM$247
- AMS$236
- UroLift System$230
- Irrisept$142
- Axonics r-SNM System$129
- SpaceOAR VUE System - 10mL$127
- XIAFLEX$123
- SOLYX$106
How this compares
$10,990 in reported general payments places this provider in the 70th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 63 | $158,327 |
| MyrbetriqMirabegron | 102 | $75,233 |
| GemtesaVibegron | 34 | $41,961 |
| Tamsulosin Hcl | 573 | $10,164 |
| Testosterone Cypionate | 58 | $2,723 |
| Testosterone | 11 | $2,303 |
| Solifenacin Succinate | 12 | $2,299 |
| Oxybutynin Chloride ErOxybutynin Chloride | 61 | $1,770 |
| Methenamine Hippurate | 16 | $1,433 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 64 | $1,364 |
| Finasteride | 90 | $1,192 |
| NitrofurantoinNitrofurantoin Macrocrystal | 26 | $817 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 118 | $750 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $472 |
| Levofloxacin | 92 | $367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $520 | $200,28897 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $75,233102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 urology providers in Tennessee.
Other urology in Nashville
- Gautam JayramNashville$16.1M
- David PensonNashville$4.4M
- L KnollNashville$2.1M
- Roger DmochowskiNashville$792K
- Melissa KaufmanNashville$617K
- Amy LuckenbaughNashville$547K
- Sam ChangNashville$461K
- Kelvin MosesNashville$452K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$345K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.